Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 5/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269571 | 0.97 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL6075340 | 0.87 | TP53 (0.48) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL7500873 | 0.84 | KDM4E (0.45) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL2624086 | 0.83 | LMNA (0.56) | KDM4EALDH1A1LMNAACHEHSD17B10 | |
| SCHEMBL5734234 | 0.83 | TP53 (0.45) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL6075321 | 0.83 | HRH2 (0.55) | KDM4EALDH1A1HPGDACHEMAPT | |
| SCHEMBL2269708 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL6075839 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1HPGDLMNAACHE | |
| SCHEMBL15921329 | 0.81 | ACHE (0.43) | LMNAACHEMAPTRAB9ABCHE | |
| SCHEMBL6075299 | 0.80 | NSD2 (0.46) | KDM4EALDH1A1HPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045526-B2 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20040063690-A1 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-04-01 | — | — | US | disclosed |
| US-6660746-B1 | Cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1150963-B1 | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2003-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063690-A1 | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them | PDE3A, PDE2A, PDE3B | KDM4E 2608/4885ALDH1A1 854/4885HPGD 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.